Matthew DeYoe

Koch pointed to a record of holding price increases but said DuPont will weigh the competitive landscape and favor volume, making no commitment to structural pricing.

Franzen said both segments delivered net productivity above 2% in the quarter.

Koch pegged R&D at ~2.5% of sales, framing changes as allocation and differential management, not cuts.

Koch confirmed healthcare up high single digits organic in Q1 on strong volume and price. Full year expected mid- to high single digits. Biopharma (Liveo) seeing nice demand recovery. Water about flat H1, up high single digits H2 on project timing, mid-single digits full year.

Koch noted constructive customer conversations on pricing with no abnormal pushback. DuPont providing documentation on input cost increases. Not looking to profit from surcharges, just covering costs. HDPE costs most impactful for Tyvek.

Koch confirmed structural pricing opportunity in most businesses going forward, though Shelter still unwinding 2022-2023 price increases. 2026 organic growth of 3% is predominantly volume with some price in select businesses.

Koch quantified 145bps of margin uplift from new products within the 30% vitality index, though declined to comment on individual product-line margins.

Koch noted Shelter was down ~2% in Q3 (adjusted), expected down 3-4% in Q4, with full year -4%. First half was weaker than second half.

Franzen clarified: Healthcare & Water reported high single digits organic (mid-single adjusted for pull-forward). Diversified Industrials reported low single digits (flat adjusted).

Beck gave no firm dollar-per-megawatt figure, repeating the directional 3 to 5x content uplift and pitching end-to-end cooling as a moat.

Beck explained the 50% gross margin math requiring roughly double the price of the cost increase; Kirkland cited high-single-digit commodity prices and a 60-basis-point Ovivo drag.

Confirmed $0.20 based on 30% base case, upside from actual faster growth. Beck addressed R&D concerns noting Ecolab's 80 years of thermal management and water expertise.

Beck confirmed top 35 customers growing 2pp above company average. Best-in-class benchmarking within customer operations is core value prop. Customers asking for more than Ecolab can currently deliver, a good problem. $3.5B share increase potential from top 35 alone.

Beck confirmed top 35 enterprise customers contributing above-average growth without specific quantification. Food & Beverage United (Hygiene + Water unified in North America) is best example, showing remarkable Q3 performance. Only North America so far, will expand globally.

Beck attributed Q2 Life Sciences margin strength to favorable biopharma mix (highest margin subsegment). Quarter-to-quarter timing of large deliveries creates variability. Reported mid-teens OI with underlying mid-20s after backing out growth investments.

Said underlying European volume is flat with no catalyst, and China moderated as expected with steel down 2.5% while electronics grew strongly.

Matthew said revenue-to-CapEx runs 20-50% depending on energy pass-through, with the new wins structured similarly to prior phases.

White distinguished between volatile energy (handled via surcharges, current situation) vs sustained increases (become structural price, like 2022). Currently surcharging. If sustained, would work into broader inflation and become permanent price.

Sanjiv broke down APAC: China manufacturing supported by large-scale exports, EVs and batteries strong (BYD growing 28%). South Pacific down but improving Q4 vs Q1-Q2. ASEAN flat linked to China weakness. India strong with trade deals resolved. Matt explained other segment: helium supply group impacted by pricing, materials business (3D printing, aerospace) performing well.

Matt said sequential timing differences are normal from contract anniversary timing. YoY pricing at 2% aligns with globally weighted inflation. Sanjiv added helium and rare gas drag in APAC is small portion of total revenue.

Sanjiv acknowledged short-term bearish outlook. But cited Germany EUR 1T commitment and potential Ukraine rebuild as longer-term positive catalysts. On-site customers still paying above MTOP.

Knavish disputed the math; Beggs sized the peso at about $15 million to $20 million, crediting price and productivity for the rest.

Knavish cited tough aerospace and packaging comps, China auto builds and European uncertainty, and still expects organic growth.

Knavish answered directly, attributing the entire decline to Refinish comps and naming the other businesses that grew.

Knavish acknowledged radical transformation in China auto (Western JVs shrinking, domestics surging) with push for Chinese supplier content. But coatings have natural protection: finished film is very hard to duplicate and reverse engineer back to resin formulation. PPG produces secret sauce outside China and ships in. Coatings' transformation during application/curing process creates buffer versus other auto parts. China auto coatings market already more competitive than elsewhere (traditional 3 plus Japanese and Korean players).

Knavish identified medical claims (pay-as-you-go spike, some 2026 pull-forward) and incentive comp catch-up (Q4 2025 came in strong on organic growth and cash vs Q4 2024 accrual drawdown). Total payout still below target. Long-term comp (TSR, restricted shares) significantly below target, offsetting short-term catch-up.

Morales clarified $75M is full-year restructuring benefits (not incremental H2), ~$30M through H1 with incremental growth in H2. Same raw material inflation rate expected. Incremental pricing in certain businesses from Q2 price increases.

Meisenzahl said guidance assumes softer for longer with no volume inflection, so stronger incremental margins wait for volume to turn and pricing is paced to inflation.

Petz said the elapsed days were not the issue, cited insufficient engagement on an all-cash offer, and left the door open post-merger at the right value.

Meisenzahl clarified the flat comparison referred to adjusted segment margin, confirming roughly half the sequential gain was non-operating.

Heidi noted organic-first approach, would opportunistically consider M&A if the right assets became available, but current focus is organic.

Al attributed the sequential dynamic to Q3 exterior gallon beat; Q4 is a seasonally smaller quarter with similar segment outlook.

Al explained 60/40 fixed-variable cost structure; H2 consumer brands gross profit reduction is 80% volume, 20% supply chain inefficiency; disciplined focus on year-end inventory to protect 2026 entry.

Bohn said roughly 50% of Blue Point CapEx is fixed through engineering, module yards and lump-sum turnkey infrastructure, with long-lead items contracted pre-FID.

Bert detailed Brazil's urea import growth from 2.5M to nearly 8M tons over 25 years, plus 8M tons ammonium sulfate. Northern plants poorly located versus demand centers, inefficient, and gas-constrained. Chris expressed skepticism about restarting idle plants given capital costs and efficiency concerns. Both agreed Brazil will remain a major importer even if some domestic capacity restarts.

Chris detailed European ammonia assets declining from 48 to roughly 30 with another 4-5 expected to close in coming years. Turnaround costs of $50-$60M force economic viability decisions. TTF at $10-$12 makes year-round production difficult when selling only 3-4 months annually. Beyond CF's Blue Point, only 2 Gulf Coast plants and 1 Qatar project are meaningful new capacity globally.

Chris estimated 3M tons of low-carbon ammonia for Asian markets by 2030, primarily power generation. Blue Point FID announcement spurring additional interest. Marine ammonia engine vessels being constructed but that application likely further out than 2030.

Bert noted 2.7M tons from Russia/Iran/Turkey and 2.6M from China expected, but offset by closures and gas shortages. Global demand growth of 1-1.5% annually requires 2-3 world-scale plants per year just to maintain balance. Chris added Chinese new plants often replace older inefficient units.